Premium
Immunoscintigraphy of prostatic cancer: Preliminary results with 111 in‐labeled monoclonal antibody 7E11‐C5.3 (CYT‐356)
Author(s) -
Wynant Gordon E.,
Murphy Gerald P.,
Horoszewicz Julius S.,
Neal Charles E.,
Collier B. David,
Mitchell Edith,
Purnell Gary,
Tyson Ian,
Heal Albert,
AbdelNabi Hani,
Winzelberg Gary
Publication year - 1991
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990180305
Subject(s) - immunoscintigraphy , medicine , immunoconjugate , monoclonal antibody , pathology , concomitant , antibody , carcinoma , cancer , prostate , urology , radioimmunotherapy , immunology
A phase 1 study was conducted with the investigational immunoscintigraphic agent, 111 In‐CYT‐356, a radiolabeled, site‐specific immunoconjugate of monoclonal antibody 7E11‐C5.3, in 40 patients with prostatic carcioma and known distant metastases. Each patient received a single intravenous infusion of CYT‐356 (dose range, 0.1–5 mg) radiolabeled with approximately 5 mCi of 111 In. None of the patients experienced adverse reactions. One patient who received a 5‐mg dose developed antibodies to the CYT‐356 immunoconjugate. 111 In‐CYT‐356 immunoscintigraphy detected bony metastases in 21 of 38 patients (55%), including 12 of 14 (86%) receiving concomitant hormonal therapy, and soft tissue lesions in four of six patients (67%). Antibody imaging detected occult lesions in the bony pelvis and lumbar spine, which were confirmed by follow‐up imaging tests, in one patient. Higher CYT‐356 doses may clear the blood pool more slowly. These results suggest that 111 In‐CYT‐356 can be safely administered to patients with prostatic carcinoma and that further clinical investigation of this agent is warranted.